Trial Information
Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma
Inclusion Criteria:
- large-cell non-Hodgkin's lymphoma
- IPI low-intermediate, high-intermediate and high or bulky mediastinum
- age 18-65
Exclusion Criteria:
- previous treatment for lymphoma
- serious concurrent systemic disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Failure-free survival
Principal Investigator
Ron Epelbaum, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
nonaffiliated
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
RonHDCHOP.CTIL
NCT ID:
NCT00192764
Start Date:
December 1996
Completion Date:
September 2010
Related Keywords:
- Non-Hodgkin's Lymphoma
- large cell lymphoma
- CHOP
- cyclophosphamide
- high-dose
- Lymphoma
- Lymphoma, Non-Hodgkin